Paul Lytle's Colleagues at Mosaic ImmunoEngineering Inc.
Paul Lytle's Contact Details
N/A
California,United States
Mosaic ImmunoEngineering Inc.
Paul Lytle's Company Details
Mosaic ImmunoEngineering Inc. is a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases. Our core technology is derived from a plant virus, cowpea mosaic virus ("CPMV") which is non-infectious to humans or other animals but upon intratumoral administration is recognized by immune cells as foreign, eliciting a strong local innate immune response through the activation of multiple toll-like receptors (TLRs). In oncology indications, this TLR activation results in potent anti-tumor activity against the primary and distant tumor sites. Our lead candidate, MIE-101, has demonstrated broad and consistent antitumor activity as a single agent and when combined with standard treatments in multiple preclinical tumor models as well as in canine companion animals with advanced cancer. Research investigating this first-in-class intratumoral multi-TLR agonist continues to be supported by numerous publications and grant funding through our university collaborators. Our technology is also being investigated as part of a modular vaccine platform, utilizing CPMV as an immune stimulant linked with viral or cancer antigens. Data generated to date show promising results in both cancer and infectious disease preclinical vaccine models, including COVID-19. The vaccine research is currently being performed by one of our co-founders and is funded by the National Science Foundation with viral neutralization testing being performed by the National Institute of Allergy and Infectious Diseases (NIAID).We are actively moving our unique technology platforms forward with the goal of filing an investigational new drug (IND) or similar application for oncology indications with the appropriate regulatory authorities to initiate clinical development of our lead candidates. Our goal is to advance our technology into veterinary and human studies in 2022.